1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Pelthos Therapeutics Inc.

Pelthos Therapeutics Inc.

PTHS
Pelthos Therapeutics Inc.US flagNew York Stock Exchange Arca
20.26
USD
+0.11
- -
77.56MMarket Cap

Total Valuation

Pelthos Therapeutics Inc. carries a market capitalization of 77.56M, placing it among publicly traded companies globally. Its enterprise value stands at 154.01M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap77.56M
Enterprise Value154.01M

Share Statistics

Pelthos Therapeutics Inc. currently has 3.72M shares outstanding.

Shares Outstanding3.72M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 2.13, and the price-to-book ratio stands at -70.01.

PE RatioN/A
PS Ratio2.13
PB Ratio-70.01
P/TBV Ratio-1.65
P/FCF Ratio-2.19
P/OCF Ratio-2.18

Enterprise Valuation

EV / Sales3.56
EV / EBITDAN/A
EV / EBITN/A
EV / FCFN/A

Financial Position

Pelthos Therapeutics Inc. maintains a current ratio of 1.98, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -4,870.69, indicating conservative leverage, while an interest coverage ratio of -7.12 demonstrates limited ability to service its debt obligations.

Current Ratio1.98
Quick Ratio1.21
Debt / Equity-4,870.69
Debt / EBITDA-1.39
Interest Coverage-7.12

Financial Efficiency

Return on Equity (ROE)N/A
Return on Assets (ROA)-125.04
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover2.56

Taxes

Income Tax-7.39M
Effective Tax RateN/A

Stock Price Statistics

Pelthos Therapeutics Inc.'s stock has declined approximately -35.68254% over the past 52 weeks. The 50-day moving average sits at 23.37, while the 200-day moving average is 24.66.

Beta (5Y)N/A
52-Week Price Change-35.68254%
50-Day Moving Average23.37
200-Day Moving Average24.66
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Pelthos Therapeutics Inc. generated 43.30M in revenue and converted that into -86.39M in net income, yielding earnings per share of -26.45. EBITDA reached -52.67M, while operating income came in at -57.78M.

Revenue43.30M
Gross Profit15.80M
Operating Income-57.78M
Pretax Income-93.78M
Net Income-86.39M
EBITDA-52.67M
EBIT-57.78M
Earnings Per Share (EPS)-26.45

Balance Sheet

Pelthos Therapeutics Inc. holds 24.19M in cash and equivalents against 73.11M in total debt, resulting in a net debt position of 45.72M. Total book value stands at -1.50M, with working capital of 31.40M providing operational flexibility.

Cash & Cash Equivalents24.19M
Total Debt73.11M
Net Debt45.72M
Equity (Book Value)-1.50M
Book Value Per Share-0.40
Working Capital31.40M

Cash Flow

Pelthos Therapeutics Inc. produced -42.30M in operating cash flow over the past twelve months. After subtracting -196,000.00 in capital expenditures, free cash flow totaled -42.50M - equivalent to -13.01 per share.

Operating Cash Flow-42.30M
Capital Expenditures-196,000.00
Free Cash Flow-42.50M
FCF Per Share-13.01

Margins

Pelthos Therapeutics Inc. operates with a gross margin of 36.48, reflecting its pricing power and cost economics. The operating margin of -133.42 and net profit margin of -199.50 provide insight into operational efficiency.

Gross Margin36.48
Operating Margin-133.42
Pretax Margin-216.56
Profit Margin-199.50
EBITDA Margin-121.63

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-68.74
FCF Yield-45.61

Stock Splits

Pelthos Therapeutics Inc.'s most recent stock split took place on July 2, 2025 with a 10:1 split ratio.

Last Split Date7/2/2025
Split Ratio10:1

Scores

Pelthos Therapeutics Inc. posts an Altman Z-Score of -3.11, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-3.11